FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313595768> ?p ?o ?g. }

• W4313595768 abstract "Physiologically, pregnancy-associated plasma protein-A (PAPP-A) serves to liberate bound IGF1 by enzymatic cleavage of IGF-binding proteins (IGFBPs), IGFBP4 in particular. Clinically, PAPP-A has been linked to cardiovascular disease (CVD). Stanniocalcin-2 (STC2) is a natural inhibitor of PAPP-A enzymatic activity, but its association with CVD is unsettled. Therefore, we examined associations between the STC2-PAPP-A-IGFBP4-IGF1 axis and all-cause mortality and CVD in patients with type 2 diabetes (T2D).We followed 1284 participants with T2D from the ADDITION trial for 5 years.Circulating concentrations of STC2, PAPP-A, total and intact IGFBP4 and IGF1 and -2 were measured at inclusion. End-points were all-cause mortality and a composite CVD event: death from CVD, myocardial infarction, stroke, revascularisation or amputation. Survival analysis was performed by Cox proportional hazards model.During follow-up, 179 subjects presented with an event. After multivariable adjustment, higher levels of STC2, PAPP-A, as well as intact and total IGFBP4, were associated with all-cause mortality; STC2: hazard ratio (HR) = 1.84 (1.09-3.12) (95% CI); P = 0.023, PAPP-A: HR = 2.81 (1.98-3.98); P < 0.001, intact IGFBP4: HR = 1.43 (1.11-1.85); P = 0.006 and total IGFBP4: HR = 3.06 (1.91-4.91); P < 0.001. Higher PAPP-A levels were also associated with CVD events: HR = 1.74 (1.16-2.62); P = 0.008, whereas lower IGF1 levels were associated with all-cause mortality: HR = 0.51 (0.34-0.76); P = 0.001.This study supports that PAPP-A promotes CVD and increases mortality. However, STC2 is also associated with mortality. Given that STC2 inhibits the enzymatic effects of PAPP-A, we speculate that STC2 either serves to counteract harmful PAPP-A actions or possesses effects independently of the PAPP-A-IGF1 axis.PAPP-A has pro-atherosclerotic effects and exerts these most likely through IGF1. IGF1 is regulated by the STC2-PAPP-A-IGFBP4-IGF1 axis, where STC2, an irreversible inhibitor of PAPP-A, has been shown to reduce the development of atherosclerotic lesions in mice. We examined the association of this axis to mortality and CVD in T2D. We demonstrated an association between PAPP-A and CVD. All components of the STC2-PAPP-A-IGFBP4-IGF1 axis were associated with mortality and it is novel that STC2 was associated with mortality in T2D. Our study supports that inhibition of PAPP-A may be a new approach to reducing mortality and CVD. Whether modification of STC2 could serve as potential intervention warrants further investigation." @default.
• W4313595768 created "2023-01-06" @default.
• W4313595768 creator A5036277718 @default.
• W4313595768 creator A5063420890 @default.
• W4313595768 creator A5064226631 @default.
• W4313595768 creator A5082250518 @default.
• W4313595768 creator A5083021518 @default.
• W4313595768 creator A5089014732 @default.
• W4313595768 creator A5089889335 @default.
• W4313595768 date "2023-03-01" @default.
• W4313595768 modified "2023-09-26" @default.
• W4313595768 title "The STC2–PAPP-A–IGFBP4–IGF1 axis and its associations to mortality and CVD in T2D" @default.
• W4313595768 cites W1976811955 @default.
• W4313595768 cites W1984538328 @default.
• W4313595768 cites W1987112016 @default.
• W4313595768 cites W2000871325 @default.
• W4313595768 cites W2003111878 @default.
• W4313595768 cites W2004317284 @default.
• W4313595768 cites W2005878233 @default.
• W4313595768 cites W2006818540 @default.
• W4313595768 cites W2010891475 @default.
• W4313595768 cites W2018753710 @default.
• W4313595768 cites W2019414394 @default.
• W4313595768 cites W2048645785 @default.
• W4313595768 cites W2048659949 @default.
• W4313595768 cites W2074444846 @default.
• W4313595768 cites W2078095800 @default.
• W4313595768 cites W2082657302 @default.
• W4313595768 cites W2087995681 @default.
• W4313595768 cites W2091479471 @default.
• W4313595768 cites W2097322870 @default.
• W4313595768 cites W2098524126 @default.
• W4313595768 cites W2099075814 @default.
• W4313595768 cites W2106250184 @default.
• W4313595768 cites W2107719587 @default.
• W4313595768 cites W2109325768 @default.
• W4313595768 cites W2111955954 @default.
• W4313595768 cites W2134293572 @default.
• W4313595768 cites W2134441573 @default.
• W4313595768 cites W2174015880 @default.
• W4313595768 cites W2226134972 @default.
• W4313595768 cites W2288300113 @default.
• W4313595768 cites W2503146299 @default.
• W4313595768 cites W2596231238 @default.
• W4313595768 cites W2606281213 @default.
• W4313595768 cites W2738160457 @default.
• W4313595768 cites W2742474598 @default.
• W4313595768 cites W2744789854 @default.
• W4313595768 cites W2769600777 @default.
• W4313595768 cites W2803878103 @default.
• W4313595768 cites W2946329427 @default.
• W4313595768 cites W2990498790 @default.
• W4313595768 cites W3002919298 @default.
• W4313595768 cites W3013559756 @default.
• W4313595768 cites W3113178943 @default.
• W4313595768 cites W3127351741 @default.
• W4313595768 cites W3196866218 @default.
• W4313595768 cites W3197828035 @default.
• W4313595768 cites W3203326469 @default.
• W4313595768 cites W4205442296 @default.
• W4313595768 cites W4226198615 @default.
• W4313595768 doi "https://doi.org/10.1530/ec-22-0451" @default.
• W4313595768 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36607154" @default.
• W4313595768 hasPublicationYear "2023" @default.
• W4313595768 type Work @default.
• W4313595768 citedByCount "1" @default.
• W4313595768 countsByYear W43135957682023 @default.
• W4313595768 crossrefType "journal-article" @default.
• W4313595768 hasAuthorship W4313595768A5036277718 @default.
• W4313595768 hasAuthorship W4313595768A5063420890 @default.
• W4313595768 hasAuthorship W4313595768A5064226631 @default.
• W4313595768 hasAuthorship W4313595768A5082250518 @default.
• W4313595768 hasAuthorship W4313595768A5083021518 @default.
• W4313595768 hasAuthorship W4313595768A5089014732 @default.
• W4313595768 hasAuthorship W4313595768A5089889335 @default.
• W4313595768 hasBestOaLocation W43135957681 @default.
• W4313595768 hasConcept C126322002 @default.
• W4313595768 hasConcept C164705383 @default.
• W4313595768 hasConcept C207103383 @default.
• W4313595768 hasConcept C2778014424 @default.
• W4313595768 hasConcept C2779134260 @default.
• W4313595768 hasConcept C2779234561 @default.
• W4313595768 hasConcept C3019714739 @default.
• W4313595768 hasConcept C44249647 @default.
• W4313595768 hasConcept C46973012 @default.
• W4313595768 hasConcept C500558357 @default.
• W4313595768 hasConcept C50382708 @default.
• W4313595768 hasConcept C54355233 @default.
• W4313595768 hasConcept C71924100 @default.
• W4313595768 hasConcept C86803240 @default.
• W4313595768 hasConceptScore W4313595768C126322002 @default.
• W4313595768 hasConceptScore W4313595768C164705383 @default.
• W4313595768 hasConceptScore W4313595768C207103383 @default.
• W4313595768 hasConceptScore W4313595768C2778014424 @default.
• W4313595768 hasConceptScore W4313595768C2779134260 @default.
• W4313595768 hasConceptScore W4313595768C2779234561 @default.
• W4313595768 hasConceptScore W4313595768C3019714739 @default.
• W4313595768 hasConceptScore W4313595768C44249647 @default.
• W4313595768 hasConceptScore W4313595768C46973012 @default.
• W4313595768 hasConceptScore W4313595768C500558357 @default.

• next